ScienceDaily (Sep. 24, 2012) ? Cancer researchers studying 44 known genetic variants associated with breast cancer have found the way to identify why they increase cancer risk, opening the door to future therapeutic applications based on personalized medicine.
The findings, published online September 24 ahead of print in Nature Genetics, fill a gap that will expand the reach of genetic profiling beyond merely screening, says principal investigator Dr. Mathieu Lupien, a scientist at Ontario Cancer Institute, the research arm of the Princess Margaret Cancer Centre at University Health Network. Dr. Lupien, who specializes in epigenetics in cancer, is also an Assistant Professor in the Department of Medical Biophysics, University of Toronto.
"Our work has identified the mechanisms altered by genetic risk variants in regions believed for a long time to be 'junk DNA'; that is, DNA outside the genes with no known function -- until now. This moves us one step closer to translating genetic profiling into patient care and advancing personalized cancer medicine," says Dr. Lupien.
"We discovered that genetic variants promoting breast cancer are found in elements with a regulatory role that modulate genes expression," he says. The team discovered the changes affecting the activity of two well known drivers of breast cancer -- the estrogen receptor ESR1 and the transcription factor FOXA1 -- that work together in breast cancer cells.
Dr. Lupien and co-investigator Dr. Jason Moore, a computational biologist at Dartmouth Medical School in Lebanon, New Hampshire, developed a methodology that identified the target of genetic predisposition by merging existing maps of the genome -- one cataloguing predisposition to breast cancer and others annotating the functional components from breast cancer cells.
"The pattern emerged revealing why genetic variants can promote breast cancer" says Dr. Lupien. "The beauty is that our methodology can be applied to any disease with known genetic predispositions. We anticipate it will be of broad benefit to other research."
The study was funded by the National Institutes for Health, the American Cancer Society, the National Cancer Institute and The Princess Margaret Hospital Foundation.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by University Health Network (UHN), via Newswise.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Richard Cowper-Sal?lari, Xiaoyang Zhang, Jason B Wright, Swneke D Bailey, Michael D Cole, Jerome Eeckhoute, Jason H Moore, Mathieu Lupien. Breast cancer risk?associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nature Genetics, 2012; DOI: 10.1038/NG.2416
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
Source: http://feeds.sciencedaily.com/~r/sciencedaily/health_medicine/genes/~3/WbvV5CUiutI/120924142434.htm
trent richardson robert griffin iii dontari poe space shuttle nyc monkeypox nick perry 30 rock live
No comments:
Post a Comment